← Back to Search

Gene Therapy

Gene Therapy-vMCO-010 for Stargardt Disease (STARLIGHT Trial)

Phase 2
Waitlist Available
Research Sponsored by Nanoscope Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
No Placebo-Only Group

STARLIGHT Trial Summary

This trial will test if a single injection of vMCO-010, a virally-carried opsin, is safe and effective in treating Stargardt Disease.

Eligible Conditions
  • Stargardt Disease

STARLIGHT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Type, severity, and incidence of ocular and systemic adverse events (AEs)
Secondary outcome measures
Effect of vMCO-010 as assessed by visual acuity
Effect of vMCO-010 on Light-guided Mobility
Effect of vMCO-010 on determination of optical flow
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

STARLIGHT Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental-vMCO-010Experimental Treatment1 Intervention
Participants receive 1.2E11gc/eye of vMCO-010
First Studied
Drug Approval Stage
How many patients have taken this drug
Gene Therapy-vMCO-010
Completed Phase 2

Find a Location

Who is running the clinical trial?

Nanoscope Therapeutics Inc.Lead Sponsor
6 Previous Clinical Trials
108 Total Patients Enrolled
1 Trials studying Stargardt Disease
6 Patients Enrolled for Stargardt Disease
Aaron Osborne, MDStudy DirectorNanoscope Therapeutics Inc.
1 Previous Clinical Trials
27 Total Patients Enrolled
Dr Samarendra MohantyStudy DirectorNanoscope Therapeutics Inc.
2 Previous Clinical Trials
62 Total Patients Enrolled

Media Library

vMCO-010 (Gene Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05417126 — Phase 2
Stargardt Disease Research Study Groups: Experimental-vMCO-010

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Gene Therapy-vMCO-010 a hazard to the health of patients?

"The safety of Gene Therapy-vMCO-010 has been assessed to be a 2, as the Phase 2 clinical trial data only provides limited evidence for its efficacy."

Answered by AI

Is enrollment available for this research trial at present?

"As documented on clinicaltrials.gov, this medical trial is not currently recruiting patients. Initially posted on the 5th of July 2022 and last updated at the end of November 2022, this study has since been superseded by 160 other active studies that are actively seeking participants."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
New Jersey
How old are they?
< 18
18 - 65
What site did they apply to?
Nanoscope Clinical Site
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I´m a young human and I need my vision for my further life. To be apart of a trial with potential to find a cure for Stargardts.
PatientReceived no prior treatments
I see pretty well so far, I want to preserve my vision and stop the disease.
PatientReceived 2+ prior treatments
~2 spots leftby Feb 2025